Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
NCT04774718Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2021
- Primary completion
- Feb 2032
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 11
01
Overview
A Phase 2 trial of alectinib in solid tumor, central nervous system tumor, sponsored by Roche. Started Sep 2021; status: active, not recruiting.
02
Drugs
alectinib
03
Conditions
solid tumorcentral nervous system tumor
Beyond the preview
Go deeper on NCT04774718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04774718.